November 23, 2014 6:37 AM ET

Biotechnology

Company Overview of Kindred Biosciences, Inc.

Company Overview

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its primary small molecule product candidates include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; and SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-007, an inhibitor of Bruton’s t...

1499 Bayshore Highway

Suite 226

Burlingame, CA 94010

United States

Founded in 2012

12 Employees

Phone:

650-701-7901

Key Executives for Kindred Biosciences, Inc.

Co-Founder
Age: 47
Total Annual Compensation: $486.3K
Co-Founder
Age: 47
Total Annual Compensation: $214.1K
Consultant
Age: 62
Total Annual Compensation: $95.3K
Compensation as of Fiscal Year 2013.

Kindred Biosciences, Inc. Key Developments

Kindred Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM

Kindred Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Kindred Biosciences, Inc. Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Receives Approval from FDA for AtoKin's New Animal Drug Application Phase 1 CMC Technical Section

Kindred Biosciences, Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of USD 6,097,000 against USD 1,212,000 a year ago. Interest income was USD 25,000 against USD 2,000 a year ago. Net loss was USD 6,072,000 against USD 1,210,000 a year ago. Net loss per share, basic and diluted was USD 0.31 against USD 0.40 a year ago. For the nine months, the company reported loss from operations of USD 20,417,000 against USD 1,832,000 a year ago. Interest income was USD 67,000 against USD 2,000 a year ago. Net loss was USD 20,350,000 against USD 1,830,000 a year ago. Net loss per share, basic and diluted was USD 1.10 against USD 0.61 a year ago. The company has received approval from the FDA for AtoKin's New Animal Drug Application Phase 1 CMC Technical Section. The company has initiated several additional programs, including SentiKin for osteoarthritis in dogs, SentiKin for dental extraction, and KIND-011 for metabolic syndrome in horses. AtoKin and SentiKin programs continue to enroll rapidly and remain on track for completion in 2015. Other programs, including programs for inappetance in cats, postoperative pain in cats, KIND-012 for fever in horses, and feline erythropoeitin, continue to advance as previously planned.

Kindred Biosciences, Inc. to Report Q3, 2014 Results on Nov 13, 2014

Kindred Biosciences, Inc. announced that they will report Q3, 2014 results After-Market on Nov 13, 2014

Similar Private Companies By Industry

Company Name Region
Nebraska Cultures, Inc. United States
ChromaTan Corporation United States
Azopax Therapeutics Inc. United States
SeqLL, LLC United States
Peninsula Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kindred Biosciences, Inc., please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.